• Je něco špatně v tomto záznamu ?

Ivacaftor in cystic fibrosis adults: Czech experience with six years of follow-up

L. Fila, L. Valentova Bartakova, A. Grandcourtova, M. Marel, R. Drnek, A. Bilkova, M. Macek, P. Drevinek

. 2016 ; 160 (2) : 276-279. [pub] 20160525

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17012968

AIMS: Ivacaftor is a revolutionary treatment option for cystic fibrosis (CF) patients with G551D and other gating mutations. The aim of this study was to evaluate the clinical status of patients on ivacaftor who were followed for up to 6 years together with an evaluation of ivacaftor therapy in one patient with an initial FEV1 less than 40% of predicted value. METHODS: Data on development of clinical status and sinopulmonary-related therapies were obtained from patient health records during ivacaftor treatment lasting for up to six years and were compared with an equivalent period before ivacaftor administration. RESULTS: Five CF adults with a median age 28.6 years (range 21.4-35.6 years) with median FEV1 45% pred. (range 16-85% pred.) were included in the study. Four subjects were also participants in the STRIVE and PERSIST studies. Altogether, twenty-four patient-years of ivacaftor treatment were analyzed. The median FEV1 decline per year decreased from -4.5 to -0.9% pred. (P = 0.043). Reduction in number of days on antibiotic treatment and hospital stays was 21% (P < 0.001) and 75% (P = 0.003), respectively. Improvement and stabilization of lung function was observed for up to six years of treatment. In a patient with severe airway obstruction, an increase in the FEV1 value (30.4% from baseline) was documented during the first twelve months of treatment. CONCLUSION: Ivacaftor therapy resulted in improved and stabilized lung function in up to six years of treatment with a reduction in number of days on antibiotic treatment and hospital stays. Its efficiency was also displayed in a patient with severe airway obstruction.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17012968
003      
CZ-PrNML
005      
20180320082020.0
007      
ta
008      
170413s2016 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2016.029 $2 doi
035    __
$a (PubMed)27226150
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Fila, Libor, $u Department of Pneumology, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic; Cystic Fibrosis Centre, University Hospital Motol, Prague, Czech Republic $d 1968- $7 ola2006345307
245    10
$a Ivacaftor in cystic fibrosis adults: Czech experience with six years of follow-up / $c L. Fila, L. Valentova Bartakova, A. Grandcourtova, M. Marel, R. Drnek, A. Bilkova, M. Macek, P. Drevinek
520    9_
$a AIMS: Ivacaftor is a revolutionary treatment option for cystic fibrosis (CF) patients with G551D and other gating mutations. The aim of this study was to evaluate the clinical status of patients on ivacaftor who were followed for up to 6 years together with an evaluation of ivacaftor therapy in one patient with an initial FEV1 less than 40% of predicted value. METHODS: Data on development of clinical status and sinopulmonary-related therapies were obtained from patient health records during ivacaftor treatment lasting for up to six years and were compared with an equivalent period before ivacaftor administration. RESULTS: Five CF adults with a median age 28.6 years (range 21.4-35.6 years) with median FEV1 45% pred. (range 16-85% pred.) were included in the study. Four subjects were also participants in the STRIVE and PERSIST studies. Altogether, twenty-four patient-years of ivacaftor treatment were analyzed. The median FEV1 decline per year decreased from -4.5 to -0.9% pred. (P = 0.043). Reduction in number of days on antibiotic treatment and hospital stays was 21% (P < 0.001) and 75% (P = 0.003), respectively. Improvement and stabilization of lung function was observed for up to six years of treatment. In a patient with severe airway obstruction, an increase in the FEV1 value (30.4% from baseline) was documented during the first twelve months of treatment. CONCLUSION: Ivacaftor therapy resulted in improved and stabilized lung function in up to six years of treatment with a reduction in number of days on antibiotic treatment and hospital stays. Its efficiency was also displayed in a patient with severe airway obstruction.
650    _2
$a dospělí $7 D000328
650    _2
$a následná péče $7 D000359
650    _2
$a aminofenoly $x terapeutické užití $7 D000627
650    _2
$a aktivátory chloridových kanálů $x terapeutické užití $7 D065101
650    _2
$a cystická fibróza $x farmakoterapie $x patofyziologie $7 D003550
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a usilovný výdechový objem $x fyziologie $7 D005541
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a chinolony $x terapeutické užití $7 D015363
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Valentová-Bartáková, Lucie $u Department of Pneumology, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic; Cystic Fibrosis Centre, University Hospital Motol, Prague, Czech Republic $7 xx0093360
700    1_
$a Grandcourtová, Alžběta $u Department of Pneumology, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic; Cystic Fibrosis Centre, University Hospital Motol, Prague, Czech Republic $7 _AN064765
700    1_
$a Marel, Miloslav, $u Department of Pneumology, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic $d 1953- $7 nlk19990073527
700    1_
$a Drnek, Radovan $u Division of Health Insurance, University Hospital Motol, Prague, Czech Republic $7 _AN077407
700    1_
$a Bilkova, Alena $u Cystic Fibrosis Centre, University Hospital Motol, Prague, Czech Republic; Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic
700    1_
$a Macek, Milan, $u Cystic Fibrosis Centre, University Hospital Motol, Prague, Czech Republic; Department of Biology and Medical Genetics, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic $d 1961- $7 mzk2006348713
700    1_
$a Dřevínek, Pavel, $u Cystic Fibrosis Centre, University Hospital Motol, Prague, Czech Republic. Department of Medical Microbiology, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic. $d 1975- $7 xx0075827
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic $x 1213-8118 $g Roč. 160, č. 2 (2016), s. 276-279
910    __
$a ABA008 $b A 1502 $c 958 $y 4 $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20180320082038 $b ABA008
999    __
$a ok $b bmc $g 1205364 $s 973741
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 160 $c 2 $d 276-279 $e 20160525 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK118 $a Pubmed-20170413

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...